{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:53:09Z","timestamp":1789843989338,"version":"4.0.1"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T00:00:00Z","timestamp":1654992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006356","name":"Syddansk Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jneuroim.2022.577913","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T21:57:07Z","timestamp":1654811827000},"page":"577913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["A prospective, one-year follow-up study of patients newly diagnosed with neurosarcoidosis"],"prefix":"10.1016","volume":"369","author":[{"given":"Keld-Erik","family":"Byg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Illes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sejbaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate L.","family":"Lambertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle H.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torkell","family":"Ellingsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2022.577913_bb0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1001\/archneur.1995.00540330053014","article-title":"Therapeutic considerations in patients with refractory neurosarcoidosis","volume":"52","author":"Agbogu","year":"1995","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1479972316661926","article-title":"Managing fatigue in sarcoidosis - a systematic review of the evidence","volume":"14","author":"Atkins","year":"2017","journal-title":"Chron Respir Dis."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis","volume":"160","author":"Baltzan","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0020","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.STR.0000258355.23810.c6","article-title":"Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis","volume":"38","author":"Banks","year":"2007","journal-title":"Stroke."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0025","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0030","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0035","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"2004079","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0040","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of Beck depression inventories -IA and -II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J. Pers. Assess."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0045","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Multiple sclerosis outcome assessments C. validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0050","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"Bitoun","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0055","series-title":"Danish Manual to SF-36. A Questionnaire About Health Status","author":"Bjorner","year":"1997"},{"key":"10.1016\/j.jneuroim.2022.577913_bb0060","first-page":"46","article-title":"Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patients","volume":"20","author":"Byg","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11020238","article-title":"Elevated Neurofilament light chain in cerebrospinal fluid and plasma reflect inflammatory MRI activity in neurosarcoidosis","volume":"11","author":"Byg","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MAO.0000000000000501","article-title":"Cranial base manifestations of neurosarcoidosis: a review of 305 patients","volume":"36","author":"Carlson","year":"2015","journal-title":"Otol Neurotol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/ajrccm.163.2.2004177","article-title":"Depression in sarcoidosis","volume":"163","author":"Chang","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0080","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"Cohen Aubart","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0085","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1378\/chest.125.3.997","article-title":"Health-related quality of life of persons with sarcoidosis","volume":"125","author":"Cox","year":"2004","journal-title":"Chest."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0090","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.rmed.2011.05.004","article-title":"Minimal (clinically) important differences for the fatigue assessment scale in sarcoidosis","volume":"105","author":"de Kleijn","year":"2011","journal-title":"Respir. Med."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.2044-8287.2012.02094.x","article-title":"Nature of fatigue moderates depressive symptoms and anxiety in sarcoidosis","volume":"18","author":"de Kleijn","year":"2013","journal-title":"Br. J. Health Psychol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0100","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: the fatigue assessment scale (FAS)","volume":"9","author":"De Vries","year":"2004","journal-title":"Br. J. Health Psychol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0105","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1378\/chest.124.5.2023","article-title":"Treatment of corticosteroid resistant neurosarcoidosis with a short-course cyclophosphamide regime","volume":"124","author":"Doty","year":"2003","journal-title":"Chest."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0110","first-page":"59","article-title":"Quality of life and depressive symptoms in patients suffering from sarcoidosis","volume":"15","author":"Drent","year":"1998","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0115","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1183\/09031936.00002512","article-title":"Sarcoidosis-associated fatigue","volume":"40","author":"Drent","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000314225","article-title":"Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment","volume":"80","author":"Elfferich","year":"2010","journal-title":"Respiration."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0125","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis","volume":"16","author":"Fritz","year":"2016","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0130","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000847","article-title":"Infliximab treatment in pathology-confirmed neurosarcoidosis","volume":"7","author":"Fritz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0135","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0140","first-page":"201","article-title":"Assessment scales in stroke: clinimetric and clinical considerations","volume":"8","author":"Harrison","year":"2013","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.jneuroim.2022.577913_bb0145","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.rmed.2017.11.008","article-title":"Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study","volume":"138s","author":"Hendriks","year":"2018","journal-title":"Respir. Med."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0150","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0155","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0160","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00415-018-8928-2","article-title":"Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results","volume":"265","author":"Kidd","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2019-002349","article-title":"Neurosarcoidosis: clinical manifestations, investigation and treatment","volume":"20","author":"Kidd","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105811","article-title":"Sarcoidosis of the central nervous system: safety and efficacy of treatment, and experience of biological therapies","volume":"194","author":"Kidd","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0175","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003277","article-title":"Neurosarcoidosis in a tertiary referral center: a cross-sectional cohort study","volume":"95","author":"Leonhard","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jneuroim.2022.577913_bb0180","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1001\/archinte.1997.00440370104011","article-title":"Diagnosis and management of neurological sarcoidosis","volume":"157","author":"Lower","year":"1997","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-3999(02)00392-6","article-title":"Psychometric qualities of a brief self-rated fatigue measure: the fatigue assessment scale","volume":"54","author":"Michielsen","year":"2003","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105855","article-title":"Evaluating S100B as a serum biomarker for central neurosarcoidosis","volume":"162","author":"Moss","year":"2020","journal-title":"Respir. Med."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0195","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/NRL.0b013e3182704d04","article-title":"Isolated neurosarcoidosis: case series in 2 sarcoidosis centers","volume":"18","author":"Nozaki","year":"2012","journal-title":"Neurologist."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0200","first-page":"98","article-title":"Psychometric evaluation of the Czech Beck depression inventory-II in a sample of depressed patients and healthy controls","volume":"38","author":"Ociskova","year":"2017","journal-title":"Neuro Endocrinol Lett."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0205","first-page":"424","article-title":"Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study","volume":"116","author":"Pietinalho","year":"1999","journal-title":"Finnish Pulmonary Sarcoidosis Study Group. Chest."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2016.09.009","article-title":"Practice effect in symbol digit modalities test in multiple sclerosis patients treated with natalizumab","volume":"10","author":"Roar","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10862-012-9309-2","article-title":"Norms for the beck depression inventory (BDI-II) in a large Dutch community sample","volume":"35","author":"Roelofs","year":"2013","journal-title":"J. Psychopathol. Behav. Assess."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0220","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archneur.64.5.691","article-title":"Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients","volume":"64","author":"Scott","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0225","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3174\/ajnr.A1470","article-title":"Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis","volume":"30","author":"Shah","year":"2009","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.acn.2005.07.003","article-title":"Normative symbol digit modalities test performance in a community-based sample","volume":"21","author":"Sheridan","year":"2006","journal-title":"Arch. Clin. Neuropsychol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106548","article-title":"Sarcoidosis: a nationwide registry-based study of incidence, prevalence and diagnostic work-up","volume":"187","author":"Sikj\u00e6r","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0240","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archneur.1985.04060080095022","article-title":"Sarcoidosis and its neurological manifestations","volume":"42","author":"Stern","year":"1985","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0245","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group","volume":"75","author":"Stern","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0250","first-page":"234","article-title":"Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials","volume":"14","author":"Strand","year":"2008","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.jneuroim.2022.577913_bb0255","first-page":"2","article-title":"Patient reported outcome measures (PROMs) in sarcoidosis","volume":"34","author":"Thunold","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0260","first-page":"2","article-title":"Everyday cognitive failure in patients suffering from neurosarcoidosis","volume":"36","author":"Voortman","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0265","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/WCO.0000000000000684","article-title":"Management of neurosarcoidosis: a clinical challenge","volume":"32","author":"Voortman","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0270","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0275","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/01.STR.0000027437.22450.BD","article-title":"Improving the assessment of outcomes in stroke: use of a structured interview to assign grades on the modified Rankin scale","volume":"33","author":"Wilson","year":"2002","journal-title":"Stroke."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0280","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis--diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM."},{"key":"10.1016\/j.jneuroim.2022.577913_bb0285","first-page":"496","article-title":"Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study","volume":"87","author":"Zaki","year":"1987","journal-title":"N Y State J Med."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:41:54Z","timestamp":1759048914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572822001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":57,"alternative-id":["S0165572822001084"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577913","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective, one-year follow-up study of patients newly diagnosed with neurosarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"577913"}}